4Kok DJ. Clinical implications of physicochemistry of stone forma tion. Endocriol Metab Clin North Am, 2002, 31: 855-867.
5Wignall GR, Cunningham IA, Denstedt JD. Coherent scatter computed tomography for structural and compositional stone analysis: a prospective comparison with infrarecl spectrosco- py. J Endourol, 2009, 23: 351-357.
6Scales CD Jr, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States[ J]. Eur Urol,2012,62 : 160-165.
7Kim YJ, Kim CH, Sung EJ, et al. Association of nephrolithiasis with metabolic syndrome and its components [ J ]. Metabolism, 2013,62:808-813.
8Lange JN, Mufarrij PW, Wood KD, et al. The association of cardiovascular disease and metabolic syndrome with nephrolithiasis [J]. Curr Opin Urol,2012,22:154-159.
9Torricelli FC, De SK, Gebreselassie S, et al. Dyslipidemia and kidney stone rlsk[J]. J Urol,2014, 191:667-672.
10Weinberg AE, Patel C J, Chertow GM, et al. Diabetic severity and risk of kidney stone disease[J]. Eur Urol,2014 ,65 :242-247.
